The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Specific BCL2 mutation confers resistance to venetoclax in progressive CLL
Piers Blombery, MBBS, FRCPA, FRACP, of University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Australia, discusses new insights into the pathobiology of venetoclax resistance in chronic lymphocytic leukemia (CLL). Dr Blombery explains how the Gly101Val mutation in BCL2 in CLL patients treated with venetoclax, as well as in in vitro binding assays, confers resistance to venetoclax. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
